{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:06:39Z","timestamp":1777773999601,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40121-026-01339-y","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:15:15Z","timestamp":1775664915000},"page":"1493-1508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Glecaprevir\/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-3499","authenticated-orcid":false,"given":"Curtis","family":"Cooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta A.","family":"Raina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liz","family":"Uribe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandru","family":"Iacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Marcinak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri","family":"Semizarov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"2","key":"1339_CR1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/hep.31060","volume":"71","author":"MG Ghany","year":"2020","unstructured":"Ghany MG, Morgan TR, Panel A-IHCG. Hepatitis\u00a0C guidance 2019 update: American American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis\u00a0C virus infection. Hepatology. 2020;71(2):686\u2013721.","journal-title":"Hepatology"},{"issue":"3","key":"1339_CR2","doi-asserted-by":"publisher","first-page":"100279","DOI":"10.1016\/j.jhepr.2021.100279","volume":"3","author":"F Girardin","year":"2021","unstructured":"Girardin F, Painter C, Hearmon N, et al. Hepatitis\u00a0C prevalences in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy. JHEP Rep. 2021;3(3):100279.","journal-title":"JHEP Rep"},{"issue":"1","key":"1339_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S2215-0366(15)00357-0","volume":"3","author":"E Hughes","year":"2016","unstructured":"Hughes E, Bassi S, Gilbody S, Bland M, Martin F. Prevalence of HIV, hepatitis\u00a0B, and hepatitis\u00a0C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(1):40\u20138.","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"1339_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S2468-1253(23)00018-3","volume":"8","author":"A Artenie","year":"2023","unstructured":"Artenie A, Stone J, Fraser H, et al. Incidence of HIV and hepatitis\u00a0C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(6):533\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1339_CR5","doi-asserted-by":"publisher","first-page":"105571","DOI":"10.1016\/j.ijantimicag.2018.10.014","volume":"56","author":"N Neant","year":"2020","unstructured":"Neant N, Solas C. Drug-drug interactions potential of direct-acting antivirals for the treatment of chronic hepatitis\u00a0C virus infection. Int J Antimicrob Agents. 2020;56(1):105571.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1339_CR6","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1186\/s12879-019-4315-6","volume":"19","author":"CL Cooper","year":"2019","unstructured":"Cooper CL, Galanakis C, Donelle J, et al. HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study. BMC Infect Dis. 2019;19(1):712.","journal-title":"BMC Infect Dis"},{"issue":"11\u201312","key":"1339_CR7","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.15011","volume":"48","author":"CH Liu","year":"2018","unstructured":"Liu CH, Yu ML, Peng CY, et al. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis\u00a0C patients in Taiwan. Aliment Pharmacol Ther. 2018;48(11\u201312):1290\u2013300.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1339_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/ejhpharm-2019-001889","volume":"28","author":"L Margusino-Framinan","year":"2021","unstructured":"Margusino-Framinan L, Cid-Silva P, Gimenez-Arufe V, et al. Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis\u00a0C virus. Eur J Hosp Pharm. 2021;28(1):16\u201321.","journal-title":"Eur J Hosp Pharm"},{"key":"1339_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/TCRM.S394467","volume":"19","author":"S Fagiuoli","year":"2023","unstructured":"Fagiuoli S, Toniutto P, Coppola N, et al. Italian real-world analysis of the impact of polypharmacy and aging on the risk of multiple drug-drug interactions (DDIs) in HCV patients treated with pangenotypic direct-acting antivirals (pDAA). Ther Clin Risk Manag. 2023;19:57\u201365.","journal-title":"Ther Clin Risk Manag"},{"key":"1339_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugpo.2018.08.013","volume":"62","author":"EB Cunningham","year":"2018","unstructured":"Cunningham EB, Amin J, Feld JJ, et al. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study. Int J Drug Policy. 2018;62:14\u201323.","journal-title":"Int J Drug Policy"},{"key":"1339_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.drugalcdep.2018.11.007","volume":"194","author":"GR Foster","year":"2019","unstructured":"Foster GR, Dore GJ, Wang S, et al. Glecaprevir\/pibrentasvir in patients with chronic HCV and recent drug use: an integrated analysis of 7 phase\u00a0III studies. Drug Alcohol Depend. 2019;194:487\u201394.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"1339_CR12","doi-asserted-by":"publisher","first-page":"ofad638","DOI":"10.1093\/ofid\/ofad638","volume":"11","author":"B Conway","year":"2024","unstructured":"Conway B, Yi S, Yung R, Sharma S. GRAND PLAN: safety and efficacy of glecaprevir\/pibrentasvir for the treatment of hepatitis\u00a0C virus infection among people initially disengaged from health care who use drugs-a systematic multidisciplinary approach. Open Forum Infect Dis. 2024;11(3):ofad638.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"1339_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","volume":"3","author":"J Grebely","year":"2018","unstructured":"Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis\u00a0C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase\u00a04, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3(3):153\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1339_CR14","unstructured":"MAVYRET (glecaprevir\/pibrentasvir). [package insert]. AbbVie, North Chicago, IL, USA. 2025."},{"key":"1339_CR15","unstructured":"MAVIRET (glecaprevir\/pibretasvir). EU summary of product charactertistics. 2025."},{"issue":"4","key":"1339_CR16","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/hep.30046","volume":"68","author":"N Reau","year":"2018","unstructured":"Reau N, Kwo PY, Rhee S, et al. Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis\u00a0C virus infection. Hepatology. 2018;68(4):1298\u2013307.","journal-title":"Hepatology"},{"issue":"4","key":"1339_CR17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12\u00a0weeks in HCV genotype\u00a01 or 3 infection. N Engl J Med. 2018;378(4):354\u201369.","journal-title":"N Engl J Med"},{"issue":"9","key":"1339_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S2468-1253(20)30086-8","volume":"5","author":"L Wei","year":"2020","unstructured":"Wei L, Wang G, Alami NN, et al. Glecaprevir-pibrentasvir to treat chronic hepatitis\u00a0C virus infection in Asia: two multicentre, phase\u00a03 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Lancet Gastroenterol Hepatol. 2020;5(9):839\u201349.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"1339_CR19","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/cid\/ciy220","volume":"67","author":"JK Rockstroh","year":"2018","unstructured":"Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients coinfected with hepatitis\u00a0C virus and human immunodeficiency virus type\u00a01: the EXPEDITION-2 study. Clin Infect Dis. 2018;67(7):1010\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1339_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","volume":"72","author":"RS Brown Jr","year":"2020","unstructured":"Brown RS Jr, Buti M, Rodrigues L, et al. Glecaprevir\/pibrentasvir for 8\u00a0weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72(3):441\u20139.","journal-title":"J Hepatol"},{"issue":"3","key":"1339_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","volume":"16","author":"T Asselah","year":"2018","unstructured":"Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of glecaprevir\/pibrentasvir for 8 or 12\u00a0weeks in patients with hepatitis\u00a0C virus genotype\u00a02, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417\u201326.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"1339_CR22","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"X Forns","year":"2017","unstructured":"Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis\u00a0C virus genotype\u00a01, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase\u00a03 trial. Lancet Infect Dis. 2017;17(10):1062\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"1339_CR23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jvh.13110","volume":"26","author":"D Back","year":"2019","unstructured":"Back D, Belperio P, Bondin M, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: an integrated analysis. J Viral Hepat. 2019;26(8):951\u201360.","journal-title":"J Viral Hepat"},{"issue":"2","key":"1339_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s40121-022-00599-8","volume":"11","author":"RS Brown Jr","year":"2022","unstructured":"Brown RS Jr, Collins MA, Strasser SI, et al. Efficacy and safety of 8- or 12\u00a0weeks of glecaprevir\/pibrentasvir in patients with evidence of portal hypertension. Infect Dis Ther. 2022;11(2):913\u201324.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"1339_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cgh.2018.07.003","volume":"17","author":"S Flamm","year":"2019","unstructured":"Flamm S, Reddy KR, Zadeikis N, et al. Efficacy and pharmacokinetics of glecaprevir and pibrentasvir with concurrent use of acid-reducing agents in patients with chronic HCV infection. Clin Gastroenterol Hepatol. 2019;17(3):527-35 e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"1339_CR26","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s40121-023-00830-0","volume":"12","author":"D Mukherjee","year":"2023","unstructured":"Mukherjee D, Collins M, Dylla DE, et al. Assessment of drug-drug interaction risk between intravenous fentanyl and the glecaprevir\/pibrentasvir combination regimen in hepatitis\u00a0C patients using physiologically based pharmacokinetic modeling and simulations. Infect Dis Ther. 2023;12(8):2057\u201370.","journal-title":"Infect Dis Ther"},{"issue":"4","key":"1339_CR27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/cts.13471","volume":"16","author":"MP Kosloski","year":"2023","unstructured":"Kosloski MP, Li H, Wang S, Mensa F, Kort J, Liu W. Characterizing complex and competing drug-drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine. Clin Transl Sci. 2023;16(4):593\u2013605.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"1339_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/infdis\/jiz439","volume":"221","author":"MP Kosloski","year":"2020","unstructured":"Kosloski MP, Oberoi R, Wang S, et al. Drug-drug interactions of glecaprevir and pibrentasvir coadministered with human immunodeficiency virus antiretrovirals. J Infect Dis. 2020;221(2):223\u201331.","journal-title":"J Infect Dis"},{"issue":"6","key":"1339_CR29","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/cpdd.671","volume":"8","author":"MP Kosloski","year":"2019","unstructured":"Kosloski MP, Zhao W, Li H, et al. Drug-drug interactions of tacrolimus or cyclosporine with glecaprevir and pibrentasvir in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(6):779\u201389.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"1339_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1124\/jpet.119.256966","volume":"370","author":"MP Kosloski","year":"2019","unstructured":"Kosloski MP, Bow DAJ, Kikuchi R, et al. Translation of in vitro transport inhibition studies to clinical drug-drug interactions for glecaprevir and pibrentasvir. J Pharmacol Exp Ther. 2019;370(2):278\u201387.","journal-title":"J Pharmacol Exp Ther"},{"key":"1339_CR31","unstructured":"University of Liverpool. Hep Drug Interactions Interaction Checker 2025. https:\/\/www.hep-druginteractions.org\/. Accessed 11 Mar 2026."},{"issue":"4","key":"1339_CR32","first-page":"148","volume":"162","author":"E Ceskova","year":"2023","unstructured":"Ceskova E, Silhan P. Therapeutic drug monitoring in psychiatry. Cas Lek Cesk. 2023;162(4):148\u201351.","journal-title":"Cas Lek Cesk"},{"issue":"1","key":"1339_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/rapm-2018-000010","volume":"44","author":"ER Viscusi","year":"2019","unstructured":"Viscusi ER. Improving the therapeutic window of conventional opioids: novel differential signaling modulators. Reg Anesth Pain Med. 2019;44(1):32\u20137.","journal-title":"Reg Anesth Pain Med"},{"issue":"4","key":"1339_CR34","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/hep.23444","volume":"51","author":"M Martinot-Peignoux","year":"2010","unstructured":"Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24\u00a0weeks to determine the sustained virologic response in patients with hepatitis\u00a0C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51(4):1122\u20136.","journal-title":"Hepatology"},{"key":"1339_CR35","unstructured":"Center for Drug Evaluation Research. Drug-Induced Liver Injury: Premarketing Clinical Evaluation 2009. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/drug-induced-liver-injury-premarketing-clinical-evaluation. Accessed 11 Mar 2026."},{"issue":"4","key":"1339_CR36","doi-asserted-by":"publisher","first-page":"ofaf174","DOI":"10.1093\/ofid\/ofaf174","volume":"12","author":"S Mollenkopf","year":"2025","unstructured":"Mollenkopf S, Rosenthal E, Teferi G, et al. Sustained impact of task-shifting HCV treatment to nonspecialist providers: 5-year follow up of the ASCEND investigation. Open Forum Infect Dis. 2025;12(4):ofaf174.","journal-title":"Open Forum Infect Dis"},{"key":"1339_CR37","doi-asserted-by":"publisher","first-page":"116032","DOI":"10.1016\/j.psychres.2024.116032","volume":"339","author":"B Rolland","year":"2024","unstructured":"Rolland B, Hallouche N, Lada O, et al. Impact of HCV cure on subsequent hospitalizations in people with mental disorders: results from the French claims database. Psychiatry Res. 2024;339:116032.","journal-title":"Psychiatry Res"},{"issue":"40","key":"1339_CR38","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.3748\/wjg.v25.i40.6094","volume":"25","author":"G Colussi","year":"2019","unstructured":"Colussi G, Donnini D, Brizzi RF, et al. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis\u00a0C virus-infected patients: a retrospective study. World J Gastroenterol. 2019;25(40):6094\u2013106.","journal-title":"World J Gastroenterol"},{"key":"1339_CR39","doi-asserted-by":"publisher","first-page":"204209862093374","DOI":"10.1177\/2042098620933741","volume":"11","author":"M Khezrian","year":"2020","unstructured":"Khezrian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence, determinants and health outcomes of polypharmacy. Ther Adv Drug Saf. 2020;11:2042098620933741.","journal-title":"Ther Adv Drug Saf"},{"key":"1339_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.drugpo.2019.01.011","volume":"66","author":"J Grebely","year":"2019","unstructured":"Grebely J, Dore GJ, Alami NN, et al. Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic hepatitis\u00a0C genotypes 1-6 receiving opioid substitution therapy. Int J Drug Policy. 2019;66:73\u20139.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1339_CR41","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s40121-021-00455-1","volume":"10","author":"A Aghemo","year":"2021","unstructured":"Aghemo A, Horsmans Y, Bourgeois S, et al. Real-world outcomes in historically underserved patients with chronic hepatitis\u00a0C infection treated with glecaprevir\/pibrentasvir. Infect Dis Ther. 2021;10(4):2203\u201322.","journal-title":"Infect Dis Ther"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01339-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01339-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01339-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:34:05Z","timestamp":1777484045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01339-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01339-y","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Curtis Cooper: speaker fees from AbbVie and Gilead; advisor for AbbVie and Gilead; unrestricted research and program funding from AbbVie and Gilead. Shweta A. Raina, Lisa Johnson, Liz Uribe, Moming Li, Alexandru Iacob, John Marcinak, and Dimitri Semizarov: employees of AbbVie and may own stock or options. Jordan J. Feld: honoraria\/research support from AbbVie, Gilead, and Atea. Ashley Brown: no relevant disclosures. Anthony Martinez: speaking fees from AbbVie, Gilead, Cepheid, Madrigal, Braeburn, and Ipsen; consulting fees from AbbVie, Gilead, Cepheid, Madrigal, Ipsen, Atea, Altimune, and Arbutus; research funding from Cepheid. Brian Conway: speaking fees from AbbVie, AstraZeneca, Gilead, GSK, Indivior Canada, Merck, Moderna, Pfizer Canada, Sanofi Pasteur, Sequiris, and ViiV; consulting for AbbVie, AstraZeneca, Gilead, GSK, Indivior Canada, Merck, Moderna, Sanofi Pasteur, Sequiris, and ViiV; research support from AbbVie, AstraZeneca, Gilead, GSK, Indivior Canada, Merck, Moderna, Sanofi Pasteur, Sequiris, and ViiV. Stuart C. Gordon, Tarik Asselah: honoraria\/research support from AbbVie, Gilead, and Atea. Stanislas Pol: speaker, consultant, and advisory board member for Janssen, Gilead, Roche, MSD, AbbVie, Biotest, Shinogi, ViiV, and French laboratory of fractionation and biotechnology (LFB); research support from Gilead, AbbVie, Roche, and MSD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies. Included studies were performed in accordance with the International Council for Harmonisation Good Clinical Practice guidelines and principles of the Declaration of Helsinki or the laws and regulations of the regions in which the research was done. Studies were approved by the institutional review boards or independent ethics committees of the participating sites. Written informed consent was obtained from all study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}